Title: Psilocybin services and mental health outcomes within Oregon's state-regulated model

Authors: Amanda Gow, MS,[1] Emily Shih PhD,[2] Ryan Reid, BS,[1] Jimmy J. Qian, MS,[2] Charan Mellor, MA,[1] Lynne Alison McInnes, MD,[2] Robin Carhart-Harris, PhD,[3] Jennie N. Davis, PhD[1,4*]

Affiliations:

1. Bendable Therapy, Bend, Oregon

2. Osmind, San Francisco, California

3. Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California

4. Center for Health Systems Effectiveness, Oregon Health & Science University

*Corresponding Author: Jennie N. Davis, Bendable Therapy, jdavis@bendabletherapy.org

Abstract

Importance: In 2020, Oregon became the first U.S. state to establish a regulated framework for

adults to access supervised psilocybin services using naturally derived mushroom products. No

studies have examined mental health outcomes among individuals receiving psilocybin in this

context.

Objectives: To evaluate changes in self-reported symptoms of depression, anxiety, and well-

being 30-days following a psilocybin session under the Oregon state-regulated model, and

document session-related adverse events and psilocybin doses consumed.

Design: A prospective, naturalistic study (March 2024-April 2025) where online surveys were

completed pre-session, 1-day, and 30-days post-psilocybin session.

Setting: Oregon psilocybin services program.

Participants: A convenience sample of adults 21 years or older participating in a psilocybin

services program: n=126 invited; n=91 enrolled.

Exposure: Legal psilocybin session.

Main Outcomes and Measures: Surveys collected demographics and medical and mental

health histories (pre-session); self-reported depression, anxiety, and well-being symptoms (pre-

session, 30-days post-session); and adverse events (e.g., hallucinogen persisting perception

disorder [HPPD]; 1-day and 30-days post-session). Main outcomes were symptoms of

depression (Patient Health Questionnaire-8), anxiety (Generalized Anxiety Disorder-7), and

well-being (World Health Organization Well-Being Index). Change in symptoms over time was

evaluated using linear mixed-effects models with timepoint as the random effect and fixed

effects of sex (male/female), concurrent psychiatric medication use (yes/no), age, and session

dose (total psilocybin equivalents [TPE, mg]: psilocybin mg + 1.39 * psilocin mg).

Results: Participants (n=88) were 43 (22,79) years (median, range), male (52.0%),

predominantly from Oregon (53.4%), psychedelic experienced (64.8%), and concurrently using

psychiatric medication (46.6%). Pre-session, 69.2% reported mild-to-severe depression, 67.0%

mild-to-severe anxiety, and 93.2% low or very low well-being. Significant improvements were

observed across all outcome measures 30-days post-session (p<0.001), including in a stratified

sensitivity analysis by concurrent psychiatric medication usage (p<0.001, all measures in both

groups). Average session dose was 27.8 mg (8.2 SD) TPE. Two participants (2.3%) reported

symptoms consistent with HPPD at 1-day post-session, but none at 30-days post-session.

Conclusions and Relevance: Psilocybin sessions delivered under the Oregon regulatory

model were associated with clinically meaningful improvements in depression, anxiety, and well-

being 30-days post-session. As other U.S. jurisdictions explore similar models, this initial real-

world evidence supports the therapeutic effectiveness of legal psilocybin services.

Introduction

      Psilocybin has emerged as a promising therapeutic intervention for mental health disorders, including depression and anxiety.[1–6] As a naturally occurring psychoactive alkaloid found in certain species of mushrooms, once ingested, psilocybin is converted to psilocin to produce its characteristic psychedelic effects by acting on serotonin receptors (e.g., 5-HT2$_A$).[7] These neuropharmacological actions are thought to underlie the improvements in mental health symptoms observed across controlled clinical trials and naturalistic observational studies.[4–6,8–17]

      Most psilocybin clinical trials enroll highly selective samples under tightly controlled conditions, typically excluding individuals with complex psychiatric diagnoses or active psychiatric medication use, and administering synthetic psilocybin within standardized dosing protocols.[4,8–12] Only one trial has used a natural mushroom formulation to examine impacts of psilocybin on alcohol use disorder, with findings highlighting the therapeutic potential of natural mushroom formulations.[18] Naturalistic studies introduce greater variability in participants' medical and psychiatric histories, session formats, and psilocybin source (often whole fruit mushrooms), yet still demonstrate improvements in depression, anxiety, and well-being[13–15,17,19,20] However, additional research bridging controlled clinical efficacy trials and real-world effectiveness is needed to understand psilocybin's mental health benefits in diverse, community-based populations.

      In 2020, Oregon voters approved Measure 109, establishing the first regulated psilocybin services model in the United States and globally. These services are administered by the Oregon Health Authority (OHA) through its Oregon Psilocybin Services (OPS) section.[21] Oregon's non-medical model permits adults 21 years and older to access psilocybin by consuming products derived from whole fruit mushrooms (*Psilocybe cubensis*) at licensed service centers under the supervision of licensed facilitators.[22] The model does not require a medical diagnosis, prescription, or clinical referral, despite mental health applications being common reasons for psilocybin use.[1] In 2025, statewide aggregate data released under Senate

Bill 303 began providing basic information, including demographics, psilocybin dosages, and

session types. However, these data do not include clinical outcomes or follow-up assessments,

limiting insight into the model's therapeutic effectiveness.

To address this gap, this study aimed to evaluate changes in self-reported symptoms of

depression, anxiety, and well-being following a psilocybin session under Oregon's regulated

model, and document session-related adverse events and psilocybin doses consumed.

Predictors of session dosage were additionally explored to understand potential correlates of

dosing decisions (e.g., participant characteristics, mental health history). Characterizing who

uses psilocybin services and with what outcomes is critical to understanding the benefits and

limitations of Oregon's regulated framework.

Methods

Setting and Participants

This prospective, naturalistic study (March 2024-April 2025) was integrated into an

existing Oregon legal psilocybin services program at Bendable Therapy ("Bendable") which

enhanced the Oregon requirements[21] by including additional screening and support sessions

(Figure 1). Individuals were invited to the study and to complete the informed consent at a

virtual interview if they met Oregon's and Bendable's eligibility criteria: aged $\geq$21 years, no

lithium use in the past 30 days (due to seizure risk[23]), no active psychosis, no active suicidal or

homicidal ideation, not pregnant or breastfeeding (Bendable only). No compensation was

provided. WCG Institutional Review Board approved this study.

Procedures and measures

A pre-session screening application (completed on average 75 days prior to the

psilocybin administration session) collected demographics, medical, mental health, psychedelic

use histories, medication usage, and validated scales assessing self-reported symptoms of

depression (Patient Health Questionnaire, PHQ-9[24]), anxiety (Generalized Anxiety Disorder,

GAD-7[25]), and well-being (World Health Organization Well-Being Index, WHO-5[26]) over the past

2 weeks (Figure 1). The PHQ-9 was modified to PHQ-8 by excluding the suicidal ideation item;

scores were adjusted accordingly.[27] On the administration session day, before consuming

psilocybin, participants completed the Imperial Psychedelic Predictor Scale (iPPS).[28] Consumed

psilocybin and psilocin doses (mg) were recorded. Additional tool and measure details are in

Supplemental Material and eTable 1.

A survey emailed to participants 30-days post-session (completed on average 34 days

post-session) included follow-up PHQ-8, GAD-7, and WHO-5 assessments, integration session

attendance, and collected information on adverse events by assessing lingering unpleasant

psychological effects attributed to the psilocybin session (i.e., anxiety, existential struggle, social

disconnection, depersonalization/derealization),[29] and assessing symptoms of Hallucinogen

Persisting Perception Disorder (HPPD),[30] a condition of enduring, distressing visual perceptions

after psychoactive substance intake[29] (also assessed in a survey sent 1-day post-session)

(Figure 1). For participants completing two sessions within the follow-up period (e.g., weeklong

retreats), data were collected according to the first session only. Online assessment were

completed via Jotform (Jotform Inc.).

Participants completed individual or group facilitator-supervised psilocybin sessions at

licensed service centers following Oregon regulations,[21] and Bendable's protocols were not

altered for this study. Psilocybin was consumed as whole mushrooms or tea made with ground

whole mushrooms. Session dosing followed Bendable's protocol of 20-30 mg psilocybin

including optional 'booster doses' (offered approximately 1-hr after initial dose). Per Oregon

rules participants may request lower or higher doses, up to a maximum of 50 mg.[31,32]

Statistical analysis

Pre-session characteristics of participants are presented as medians (range) or

frequencies (proportions). Primary outcomes were change in mental health status from pre-

session to 30-days post-session using the PHQ-8, GAD-7, and WHO-5 scales. Clinically

significant depression and anxiety were defined as scores >10, and poor well-being as scores

<13 (Supplemental Material).

Per Oregon regulations, mushrooms were grown, processed, and potency-tested for

analyte content (psilocybin and psilocin) in Oregon licensed facilities; product packaging listed

analyte content in milligrams per gram of whole mushroom.[32] Oregon regulations define dose by

psilocybin content; because psilocybin rapidly converts to its pharmacologically active form of

psilocin once ingested,[7] Bendable calculates dose as Total Psilocybin Equivalents (TPE =

psilocybin mg + 1.39 × psilocin mg), a metric assuming complete conversion of psilocybin to

psilocin based on molecular weight.[33] We report both TPE and psilocybin dose.

We used separate linear mixed effects models to evaluate changes in outcomes across

two timepoints (means, SE). Timepoint was modeled as a categorical variable (pre-session as

reference), with birth sex (male/female), age (years), concurrent psychiatric medication use

(yes/no), and dose (TPE, mg) included as fixed effects. Participant-level random intercepts and

slopes accounted for individual differences in pre-session symptom levels and change over

time. Effect sizes 30-days post session (relative to pre-session) were calculated using Cohen's

d, and classified as small (0.20-0.49), moderate (0.50-0.79), large ($\geq$0.80), or very large ($\geq$1.2).[34]

A post-hoc simulation-based power analysis (α=0.05) indicated approximately 100% power for

large effects and 89% for small effects.

Sensitivity and exploratory analyses

In a sensitivity analysis, we repeated the adjusted models substituting TPE with

psilocybin dosage to assess robustness to an alternative dose specification. In a second

analysis to assess whether findings were driven by participants with additional dosing, we

restricted the sample to participants who completed a single session during the study period

(n=75), excluding those with multiple sessions (n=13). In a third analysis, we stratified the

sample by concurrent psychiatric medication use and repeated the adjusted models separately

among participants with (n=41) and without (n=47) pharmacotherapy to descriptively assess

whether patterns of outcomes were consistent across medication status.

To explore correlates of dosing decisions, we used univariate linear regression models

to examine predictors of session dose (TPE). Predictors included pre-session PHQ-8, GAD-7,

and WHO-5 scores; age; birth sex; most commonly reported diagnoses: depression, anxiety,

post-traumatic stress disorder (PTSD); concurrent psychiatric medication use; and prior

psychedelic experience.[14] In a separate multivariate regression model, iPPS subscales were

entered simultaneously to assess their independent contributions to TPE. Given these analyses'

exploratory nature, p-values were not adjusted for multiple comparisons.

Analyses were conducted using R/R Studio version 4.4.2 (R Foundation), and included

only participants who completed pre- and post-session surveys (n=3 excluded); we set

statistical significance at $p<0.05$.

Results

Participant demographics, mental health history and psychedelic experience

During the study period, n=311 screening applications were received. Of these, n=126

individuals met psilocybin services' eligibility criteria and were invited to participate, n=91

enrolled, and n=88 completed all study components. Participants (n=88) ranged in age from 22-

79 years (median: 43 years), were approximately balanced by birth sex and gender identity

(52.0% male; 50.0% male-identifying), and were predominantly White (87.5%), educated

(84.1% with higher education), and employed (67.1%), with only 22.7% reporting annual

household income below $50,000 **(Table 1)**. Most participants lived in Oregon (53.4%) and

15.9% were military veterans. Depression (51.1%), anxiety (42.0%), and PTSD (19.3%) were

the most reported mental health diagnoses. Almost half (46.6%) reported concurrent use of

psychiatric medications (medication type and dosage were not systematically collected) and

participation in therapy (56.8%). The majority (64.8%) had prior psychedelic experience, and

cost was the most frequently reported barrier to seeking psilocybin services (46.6%) (Table 1).

Most participants completed individual sessions (56.8%) rather than group sessions (43.2%),

and 80.0% completed at least one integration session during follow-up.

Mental health outcomes after a psilocybin session

We examined whether participation in a psilocybin session was associated with changes

in mental health outcomes. Pre-session, 69.2% of participants reported mild to severe

depression symptoms, 67.0% reported mild to severe anxiety symptoms, and 93.2% reported

low or very-low sense of well-being, reflecting clinically significant symptom levels across all

measures **(Table 2)**. At approximately 30-days post-session, improvements were observed

across all measures, with 61.4% of participants reporting minimal depression, 70.5% reporting

minimal anxiety, and 64.8% reporting normal levels of well-being.

Modeling results similarly reflected significant improvements in mental health outcomes

over time (**Figure 2**, **eTable 2 in Supplement**). PHQ-8 and GAD-7 mean scores significantly

decreased pre-session to 30-days post-session, suggesting robust declines in depression and

anxiety symptoms: PHQ-8 score change of -4.63 (0.57 SE) points; $p<0.001$; $d=0.90$ (95% CI:

0.68, 1.12) large; GAD-7 score change of -4.85 (0.57) points; $p<0.001$; $d=1.04$ (0.80, 1.17)

large. WHO-5 well-being scores also improved at follow-up with a score change of +10.67

(0.59) points; $p<0.001$; $d=-2.14$ (-2.38, -1.90) very large), indicating significant gains in well-

being. Of the covariates examined, only concurrent psychiatric medication use was positively

associated with post-session PHQ-8 scores ($p=0.040$).

Sensitivity analyses, one substituting psilocybin for TPE as the dose covariate in all

outcomes models and another limited to participants who completed a single administration

session (n=75), yielded results consistent with the primary analysis, with no change in the

direction or magnitude of timepoint effects. In a third sensitivity analysis, results from stratified

models by concurrent psychiatric medication use were largely consistent with those from the full

cohort, with significant post-session improvement across all outcomes observed in both groups

(p<0.001). Overall, these findings support the robustness of the primary results **(eTables 3-5 in**

Supplement).

Post-session adverse events

Participants (n=35, 39.7%) reported symptoms of HPPD at 1-day post-session, and two

(2.3%) indicated these symptoms caused significant distress and were attributed to the

psilocybin session, potentially meeting diagnostic HPPD criteria. Fewer participants (n=16,

18.2%) reported HPPD symptoms at 30-days post-session, with none reporting the symptoms

caused significant distress. Three (3.4%) participants reported lingering negative effects of the

psilocybin experience, noting increased feelings of anxiety or fear, existential struggle, social

disconnections, and difficulty coping with family members.

Session dose and exploratory analyses predicting psilocybin session dose

The average dose (TPE) consumed by participants was 27.8 mg (8.2 SD), and was 24.3

mg (8.3 SD) when restricted to psilocybin **(Table 3).** In exploratory analyses examining

predictors of dose (TPE), the only significant predictor was concurrent use of psychiatric

medications, which was associated with greater administered dose (*b*=3.44, *p*<0.05, **eTable 6**

in Supplement); these participants received an average dose of 29.6 mg TPE (26.2 mg TPE for

those not taking psychiatric medications). No iPPS subscales were significantly associated with

dose (**eTable 7 in Supplement**).

Discussion

This prospective, naturalistic study presents the first results examining the impact of

psilocybin on mental health outcomes within Oregon's state-regulated model. We found that at

30-days post-psilocybin session, participants reported significant reductions in depression and

anxiety symptoms and significant improvements in well-being. These benefits were observed in

a community-based population that included individuals with multiple psychiatric diagnoses and

those actively using psychiatric medications, populations often excluded from research of

psilocybin's impact on mental health. Our findings suggest that psilocybin services delivered

within a structured and supportive framework can produce therapeutic benefits. This

translational evidence is needed to inform policy and clinical implementation as jurisdictions

worldwide consider regulated psilocybin programs.

As a therapeutic intervention, psilocybin is particularly effective when combined with

therapeutic support,[1–4] though therapeutic support is not uniformly included in studies of

psilocybin's impact on mental health.[1] The results of this study were achieved under Bendable's

enhanced, supportive model relative to the minimum requirements set forth under Oregon's

Measure 109 through incorporating comprehensive screening, multiple preparation sessions,

and structured integration support with licensed facilitators of which many held additional clinical

health licenses. Such enhancements potentially influenced the overall significant improvements

in mental health outcomes among study participants, including limited adverse events and few

reports of psychedelic harm, which is consistent with prior studies.[35] Research also indicates

that integrative psychological support and facilitated processing after psychedelic-assisted

sessions increase the likelihood of sustained benefits.[36,37]

Study participants demonstrated clinically significant improvements in self-reported

symptoms of depression, anxiety, and well-being. At 30-days post-session, 65% of participants

reported normal well-being despite approximately one-third continuing to report mild to severe

symptoms of depression or anxiety. Because the WHO-5 Well-Being Index captures mental and

emotional domains related to psychological flexibility and adaptive functioning,[26] these findings

may suggest a growing capacity for change and emerging emotional resilience, which are

domains of functioning that individuals may particularly value.[38] Other studies of the impacts of

psilocybin on well-being likewise reported increased well-being or life satisfaction post-

psilocybin session.[39]

Consistent with our results, a recent naturalistic study of U.S. veterans attending

psychedelic retreats outside the U.S. documented clinically significant reductions in depression

with the PHQ-9 one-month post-psychedelic session, though not all participants consumed

psilocybin as the psychedelic substance (some received ayahuasca).[13] A naturalistic study from

Germany similarly reported significant improvements in depression (PHQ-9) and anxiety (GAD-

7) symptoms following a psilocybin session, with an approximate 25 mg psilocybin dose from

fresh mushrooms, though follow-up timepoints were at 1 week and 3 months.[14] This study

included participants with multiple psychiatric diagnosis, which is less common in clinical

trials.[40,41] In our study, nearly two-thirds of participants had mental health diagnoses, many

concomitant, and few experienced post-session adverse events, adding to the extant evidence

that psilocybin services can be safely delivered to populations experiencing a range of mental

health conditions in real-world settings.

In clinical trials, dose is standardized and often fixed at 25 mg of synthetic

psilocybin,[5,8,40,42,43] including the recent COMPASS Pathways Phase 3 COMP005 trial (25).[16]

The average doses administered in our study (27.8 mg TPE, 24.3 mg psilocybin) were

comparable to trials' standard dose, and outcomes were similar whether assessed by TPE or

psilocybin content alone. The novel dosing protocol described in our study, which accounts for

both psilocybin and psilocin content, provides a useful framework for other states developing

regulated programs utilizing natural-derived mushroom products, and may inform policy

decisions regarding maximum dose limits. While Oregon's legal maximum is 50 mg, this study

demonstrated meaningful improvements in outcomes with limited adverse events at an average

dose below 30 mg TPE, suggesting that lower doses may be both effective and well-tolerated in

real-world settings. Additional research is needed to confirm both safety and efficacy of this

dosing practice, and among a greater diversity of populations than was included in this study.

Individuals taking psychiatric medications are often excluded from clinical trials to reduce

the risk of a psilocybin blunting effect, allow for uniform dosing, and minimize the risk of

serotonin toxicity.[33,44] Two psilocybin clinical trials have examined the impacts on participants

taking psychiatric medications, and found reduced depressive symptoms[42] and reduced adverse

effects of psilocybin.[45] We found that participants using psychiatric medications consumed

modestly higher average doses. Sensitivity analyses restricted to this subgroup yielded results

consistent with the main findings, suggesting concurrent psychiatric medication use did not

substantially alter treatment response. While this may suggest that psilocybin services using

whole-fruit mushroom products may be effective at improving mental health outcomes without

requiring psychiatric medication discontinuation, additional controlled research examining

psychiatric medications and doses, and explicitly testing moderation effects, is needed.[46]

Strengths and limitations

This study has several notable strengths. It represents the first systematic evaluation of

mental health outcomes following psilocybin administration within the first regulated framework

in the US, and the first to quantify both psilocybin and psilocin content in administered doses.

This real-world study design provides evidence of effectiveness in naturalistic settings with

individuals with mental health complexities thereby offering a realistic assessment of treatment

benefits that complement traditional efficacy data.[47] Rigorous data collection and participant

follow-up yielded near-complete retention, with data from only three participants excluded.

Within-person pre–post assessments reduced between-person confounding, and the use of

widely implemented validated instruments for depression, anxiety, and well-being supports

comparison with prior studies.

Limitations of the study include its small sample size and the predominance of

participants residing in Oregon, impacting its generalizability. However, the study was

adequately powered to detect medium to large effect sizes in change in mental health

symptoms, supporting the robustness of the observed results. As an observational study without

a control group, causality cannot be inferred, and placebo effects, self-selection bias,

expectancy bias, and unmeasured confounding factors (such as influential participant lifestyle or

situational changes during the study period) cannot be ruled out. Also, the follow-up period was

limited to 30-days post-session; although this duration aligns with many clinical trials and

observational studies,[4,10,13,40] longer-term effects remain to be determined and should be

investigated in future studies conducted within Oregon's regulated model.

Conclusion

In this prospective, naturalistic study, we found that carefully screened participants who

underwent a supervised psilocybin session within Oregon's regulated framework and consumed

naturally-derived mushroom products experienced significant improvements in depression,

anxiety, and overall well-being with few adverse events, even among those with concurrent use

of psychiatric medications and complex mental health histories. These findings demonstrate that

psilocybin can be delivered safely and effectively in real-world settings, broadening the potential

accessibility of psilocybin services as a tool to bridge clinical and community care. For Oregon,

these data strengthen confidence in the state's pioneering regulatory framework, offering data-

driven guidance for establishing standardized practices in supportive psilocybin service

frameworks, while advancing policy goals to safely expand this emerging mental health field.

Acknowledgements

Author Contributions: A.G., R.R. J.J.Q, L.A.A., R.C.H, and J.N.D. designed the study. A.G.,

R.R., C.M., and J.N.D. collected the data. E.S. conducted data analysis. A.G., E.S., R.R. J.J.Q.,

and J.N.D. interpreted the data. A.G., E.S., R.R., and J.N.D. wrote the initial draft of the

manuscript. All authors critically reviewed the manuscript and approved the final draft. J.N.D. is

accountable for all aspects of the study and manuscript.

Funding/Support: This research was financially supported in part by the Jurveston Foundation.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study;

collection, management, analysis, and interpretation of the data; preparation, review, or

approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank the participants for their time, trust, and willingness to

share their experiences. We also acknowledge the valuable contributions of the Bendable

Therapy team members who supported data collection: Brooke Harralson, River Jenkins, Sam

Georgi, and Matt Hailey. These individuals did not receive additional compensation for these

contributions.

References

1. Dorczok MC, Mittmann G, Ettl T, Steiner-Hofbauer V. Psilocybin-assisted psychotherapy in adults with depression – A literature review. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2025;142:111508. doi:10.1016/j.pnpbp.2025.111508

2. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *The Lancet Psychiatry*. 2016;3(7):619-627. doi:10.1016/S2215-0366(16)30065-7

3. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. *Psychopharmacology*. 2018;235(2):399-408. doi:10.1007/s00213-017-4771-x

4. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *J Psychopharmacol*. 2016;30(12):1181-1197. doi:10.1177/0269881116675513

5. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. *New England Journal of Medicine*. 2022;387(18):1637-1648. doi:10.1056/NEJMoa2206443

6. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. *Journal of Affective Disorders*. 2023;327:120-127. doi:10.1016/j.jad.2023.01.108

7. Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. *Addict Biol*. 2002;7(4):357-364. doi:10.1080/1355621021000005937

8. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. *New England Journal of Medicine*. 2021;384(15):1402-1411. doi:10.1056/NEJMoa2032994

9. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J Psychopharmacol*. 2016;30(12):1165-1180. doi:10.1177/0269881116675512

10. Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. 2021;78(5):481-489. doi:10.1001/jamapsychiatry.2020.3285

11. Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. *JAMA*. 2023;330(9):843-853. doi:10.1001/jama.2023.14530

12. von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. *eClinicalMedicine*. 2023;56:101809. doi:10.1016/j.eclinm.2022.101809

13.   Calnan M, Blest-Hopley G, Busch C, et al. Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings. *Brain and Behavior*. 2025;15(7):e70660. doi:10.1002/brb3.70660

14.   Irrmischer M, Puxty D, Yıldırım BO, Deijen JB, Engelbregt H. Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation. *Psychopharmacology (Berl)*. 2025;242(4):725-740. doi:10.1007/s00213-024-06733-3

15.   de la Salle S, Kettner H, Thibault Lévesque J, et al. Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy. *Sci Rep*. 2024;14(1):16524. doi:10.1038/s41598-024-66817-0

16.   Compass. Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression. Accessed October 12, 2025. https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx

17.   Nygart VA, Pommerencke LM, Haijen E, et al. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. *J Psychopharmacol*. 2022;36(8):932-942. doi:10.1177/02698811221101061

18.   Jensen ME, Stenbæk DS, Messell CD, et al. Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study. *J Psychopharmacol*. 2025;39(5):463-473. doi:10.1177/02698811251319457

19.   Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. *J Psychopharmacol*. 2023;37(1):49-60. doi:10.1177/02698811221131997

20.   Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: A scoping review. *J Psychopharmacol*. Published online September 12, 2025:02698811251368360. doi:10.1177/02698811251368360

21.   Oregon Health Authority. Oregon Psilocybin Services. Accessed October 11, 2025. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Oregon-Psilocybin-Services.aspx

22.   Oregon Health Authority. Public Health Division-Chapter 333, Division 333 Psilocybin, Client Information Form. Accessed October 11, 2025. https://secure.sos.state.or.us/oard/viewSingleRule.action?ruleVrsnRsn=319978

23.   Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR. Classic Psychedelic Coadmination with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. *Pharmacopsychiatry*. 2021;54:240-245. doi:10.1055/a-1524-2794

24.   Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med*. 2001;16(9):606-613. doi:10.1046/j.1525-1497.2001.016009606.x

25.   Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092-1097. doi:10.1001/archinte.166.10.1092

26.   Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. *Psychother Psychosom*. 2015;84(3):167-176. doi:10.1159/000376585

27.   Shin C, Lee SH, Han KM, Yoon HK, Han C. Comparison of the Usefulness of the PHQ-8 and PHQ-9 for Screening for Major Depressive Disorder: Analysis of Psychiatric Outpatient Data. *Psychiatry Investig*. 2019;16(4):300-305. doi:10.30773/pi.2019.02.01

28.   Angyus M, Osborn S, Haijen E, et al. Validation of the imperial psychedelic predictor scale. *Psychol Med*. 54(12):3539-3547. doi:10.1017/S0033291724002204

29.   Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. *J Psychopharmacol*. 2022;36(3):258-272. doi:10.1177/02698811211069100

30.   Zhou K, de Wied D, Carhart-Harris RL, Kettner H. Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use. *PNAS Nexus*. 2025;4(4):pgae560. doi:10.1093/pnasnexus/pgae560

31.   Oregon Psilocybin Services. Oregon Psilocybin Services: Health and Safety Fact Sheet. Published online May 2025. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/OPS-Health-and-Safety.pdf

32.   Oregon Psilocybin Services. Oregon Psilocybin Services (OPS) Psilocybin Product Potency Information. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/OPS-Psilocybin-Product-Potency-Information.pdf

33.   MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: Practical considerations for dosing and administration. *Front Psychiatry*. 2022;13:1040217. doi:10.3389/fpsyt.2022.1040217

34.   Cohen J. Quantitative Methods in Psychology: A power primer. *Psychol Bull*. 1992;112(1):155-159. doi:10.1037//0033-2909.112.1.155

35.   Evans J, Aixalà M, Anderson BT, et al. On Minimizing Risk and Harm in the Use of Psychedelics. *Psychiatr Res Clin Pract*. 2025;7(1):4-8. doi:10.1176/appi.prcp.20240128

36.   Gorman I, Nielson EM, Molinar A, Cassidy K, Sabbagh J. Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. *Front Psychol*. 2021;12. doi:10.3389/fpsyg.2021.645246

37.   Greń J, Gorman I, Ruban A, Tylš F, Bhatt S, Aixalà M. Call for evidence-based psychedelic integration. *Experimental and Clinical Psychopharmacology*. 2024;32(2):129-135. doi:10.1037/pha0000684

38.   Connell J, O'Cathain A, Brazier J. Measuring quality of life in mental health: Are we asking the right questions? *Social Science & Medicine*. 2014;120:12-20. doi:10.1016/j.socscimed.2014.08.026

39.   Wiepking L, Bruin E de, Ghiţă A. The potential of psilocybin use to enhance well-being in healthy individuals – A scoping review. Published online November 29, 2023. doi:10.1556/2054.2023.00244

40.   Rosenblat JD, Meshkat S, Doyle Z, et al. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. *Med*. 2024;5(3):190-200.e5. doi:10.1016/j.medj.2024.01.005

41.   Aaronson ST, van der Vaart A, Miller T, et al. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial. *JAMA Psychiatry*. 2024;81(6):555-562. doi:10.1001/jamapsychiatry.2023.4685

42.   Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. *Neuropsychopharmacol*. 2023;48(10):1492-1499. doi:10.1038/s41386-023-01648-7

43.   Back AL, Freeman-Young TK, Morgan L, et al. Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. *JAMA Netw Open*. 2024;7(12):e2449026. doi:10.1001/jamanetworkopen.2024.49026

44.   Malcolm B, Thomas K. Serotonin toxicity of serotonergic psychedelics. *Psychopharmacology*. 2022;239(6):1881-1891. doi:10.1007/s00213-021-05876-x

45.   Becker AM, Holze F, Grandinetti T, et al. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. *Clin Pharmacol Ther*. 2022;111(4):886-895. doi:10.1002/cpt.2487

46.   Erritzoe D, Barba T, Spriggs MJ, Rosas FE, Nutt DJ, Carhart-Harris R. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. *J Psychopharmacol*. 2024;38(5):458-470. doi:10.1177/02698811241237870

47.   McInnes LA, Marton TF, Qian JJ. Embracing pragmatism for ketamine insurance coverage: Leveraging real-world evidence. *Journal of Affective Disorders*. 2024;352:199-200. doi:10.1016/j.jad.2024.02.033

Tables

Table 1: Participant demographic, mental health, and psychedelic experience characteristics[a]

Demographic Characteristics	Session Participants (n=88)
Age, years (median, range)	43 (22, 79)
Birth sex, No. (%)	
Male	46 (52.0)
Female	41 (46.6)
Gender, No. (%)	
Male	44 (50.0)
Female	40 (45.5)
LGBTQIA+	3 (3.4)
Race[b] , No. (%)	
White	77 (87.5)
American Indian or Alaska Native	1 (1.1)
Mixed/multiple races	3 (3.4)
Ethnicity, No. (%)	
Non-Hispanic/Non-Latinx	77 (87.5)
Hispanic-Latinx	5 (5.7)
Level of education completed, No. (%)	
Graduate or professional degree	31 (35.2)
College or baccalaureate degree	32 (36.4)
Associate's or technical degree	11 (12.5)
High school or some college	13 (14.8)
Employment, No. (%)	
Employed (full-time, part-time, self-employed, or sporadically)	59 (67.1)
Retired	17 (19.3)
Unemployed/on disability	9 (10.2)
Student	1 (1.1)

Annual household income, No. (%)	
≥ $100,000	30 (34.1)
$50,000-$99,999	25 (28.4)
$10,000-$49,000	18 (20.4)
< $10,000	2 (2.3)
Decline to Answer	13 (14.8)
Residence, No. (%)	
Living in Oregon	47 (53.4)
Living in other U.S. state	40 (45.5)
Living internationally	1 (1.1)
Military veteran, No. (%)	14 (15.9)
Mental Health Characteristics	
Reported mental health diagnosis, No. (%)	
Depression	45 (51.1)
Anxiety	37 (42.0)
PTSD	17 (19.3)
Acute Stress	6 (6.8)
OCD	4 (4.5)
Eating disorder	2 (2.3)
Bipolar disorder[c]	1 (1.1)
Other	6 (6.8)
No mental health diagnosis	32 (36.4)
Currently taking psychiatric medications, No. (%)	41 (46.6)
Currently in therapy, No. (%)	50 (56.8)
Psychedelic Characteristics	
Prior psychedelic experience, No. (%)	57 (64.8)
Barriers to seeking psilocybin services, No. (%)	
Cost	41 (46.6)

Availability	16 (18.2)
Time and schedule	21 (23.9)
Limited knowledge and experience of psychedelics	16 (18.2)
Current support systems in place (or not in place)	6 (6.8)
Legal concerns	4 (4.5)
Judgement from family and peers	4 (4.5)
Current mental health concerns	4 (4.5)
No concerns	28 (31.8)
Other	1 (1.1)

[a] Some categories of characteristics may not add to 100% as some participants declined to answer demographic questions and data are missing. All data is from the screening application, which gathered data at baseline (prior to a psilocybin administration session). Abbreviations: LGBTQIA+, Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual, all other identities not explicitly mentioned; OCD, obsessive compulsive disorder; PTSD, post-traumatic stress disorder.

[b] Race variable was a "select all that apply" field. Participants who selected more than one race were grouped into a "Mixed / Multiple race" option and custom responses that didn't match the standard categories were grouped into "Other".

[c] Participants who listed bipolar disorder as a mental health diagnosis in their screening application were subsequently screened by Bendable. Those who never had a formal diagnosis of bipolar disorder and were otherwise eligible were allowed to continue to a psilocybin session.

Table 2: Participant classification by PHQ-8, GAD-7, and WHO-5 categories pre- and post-psilocybin session[a]

Participant Classification Category	Pre-Session (n=88)	30-days Post-Session (n=88)
PHQ-8 (depression), No. (%)		
Minimal	27 (30.7)	54 (61.4)
Mild-Moderate	45 (51.1)	31 (35.2)
Moderately Severe-Severe	16 (18.1)	3 (3.4)
GAD-7 (anxiety), No. (%)		
Minimal	29 (33.0)	62 (70.5)
Mild-Moderate	44 (50)	25 (28.4)
Severe	15 (17.0)	1 (1.1)
WHO-5 (well-being), No. (%)		
Normal	6 (6.8)	57 (64.8)
Borderline	0 (0)	9 (10.2)
Low-very low	82 (93.2)	22 (25.0)

[a] Participants completed online surveys that contained the 3 mental health questionnaires (PHQ-8, GAD-7, WHO-5) at two timepoints: pre-session and approximately 30-days post-psilocybin administration session. Pre-session surveys were completed, on average, 75 days prior to the psilocybin administration session; 30-day post-session surveys were completed, on average, 34 days after the psilocybin administration session. Abbreviations: GAD-7, Generalized Anxiety Disorder-7; PHQ-8, Patient Health Questionnaire-8; WHO-5, World Health Organization-5 Well-Being index.

Table 3: TPE and psilocybin doses consumed by participants during a legal psilocybin session in Oregon[a]

Dose Type	Dose, mg
TPE dose, mean (SD)	27.8 (8.2)
TPE dose, median (min, max)	29.9 (13.9, 50.2)
Psilocybin dose, mean (SD)	24.3 (8.3)
Psilocybin dose, median (min, max)	22.0 (9.1, 44.6)

[a] TPE, Total Psilocybin Equivalents, is defined as psilocybin (mg) + 1.39 × psilocin (mg). This metric assumes complete conversion of psilocybin to psilocin based on molecular weight.

Figures

Figure 1. Study components within the framework of a legal psilocybin services program in Oregon

Figure 1 Footnote: Study components were integrated into an existing legal psilocybin services program in Oregon, Bendable Therapy. Oregon regulatory minimums require one facilitator-client preparation session 24-hours in advance of a psilocybin administration session and to offer an optional integration session post-administration.[21] The study site psilocybin program included additional comprehensive screening, multiple preparation sessions, and structured integration support sessions with licensed facilitators of which many held additional clinical health licenses. Abbreviations: GAD-7, Generalized Anxiety Disorder-7 questionnaire; HPPD, Hallucinogen Persisting Perception Disorder; PHQ-8, Patient Health Questionnaire-8; iPPS, Imperial Psychedelic Predictor Scale; WHO-5, World Health Organization Well-Being-5 Index.

Figure 2 Title: PHQ-8, GAD-7, and WHO-5 estimated marginal mean scores before and 30-days following a legal psilocybin session in Oregon

Figure 2 Footnote: Scores from the PHQ-8 (depression), GAD-7 (anxiety), and WHO-5 (well-being) questionnaires are represented as estimated marginal means with error bars indicating standard errors. Adjusted linear mixed effects models evaluated change in outcomes, with all models significant at p<0.001. Score data were collected from surveys emailed to participants prior to a psilocybin session (completed on average 75 days before the session) and approximately 30-days after the psilocybin session (completed on average 34 days post-session). Abbreviations: GAD-7, Generalized Anxiety Disorder-7; PHQ-8, Patient Health Questionnaire-8; WHO-5, World Health Organization Well-Being Index-5.